IASLC: Ivonescimab vs Pembrolizumab as First-Line Treatment in …
WEBIvonescimab is a bispecific antibody targeting both PD-1 and the vascular endothelial growth factor (VEGF). It showed activity as front-line therapy in the phase II AK112-202 study. 2 The phase III HARMONi-2 trial randomly assigned 398 patients from 55 centers in China to receive either ivonescimab (20 mg/kg) or pembrolizumab (200 mg) every 3 ...
Promising Anti-Tumor Activity and Safety of Ivonescimab in …
WEB6 days ago · The presentation was entitled, The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC), presenting the current ...
Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in …
WEBSep 8, 2024 · Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated …
WEBSep 8, 2024 · Ivonescimab has been approved in China for treating EGFR mutated locally advanced or metastatic non-squamous NSCLC patients who have progressed after EGFR TKI treatment. It is the world's...
Summit therapy beat Merck blockbuster Keytruda in late-stage …
WEBSep 8, 2024 · The Summit drug, an antibody called ivonescimab, reduced the risk of tumor progression by 49% compared to Keytruda, according to data released here at the World Conference on Lung Cancer.
Akeso’s Ivonescimab plus Chemo in First-Line Triple ... - BioSpace
WEB6 days ago · HONG KONG, Sept. 16, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC).The preliminary data, with only a 10-month median follow-up, revealed that the ivonescimab combination regimen ...
Ivonescimab outperforms pembrolizumab in study for first-line …
WEBSep 8, 2024 · Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for...
Ivonescimab Tops Pembro in Advanced PD-L1-Positive NSCLC
WEBSep 8, 2024 · Ivonescimab (AK112) is a novel, potentially first-in-class investigational bi-specific antibody that targets programmed death 1 (PD-1) and vascular endothelial growth factor (VEGF) developed by...
Ivonescimab Monotherapy Decisively Beats Pembrolizumab …
WEBMay 30, 2024 · Ivonescimab, known as AK112 is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis...
Akeso Published First-Ever Efficacy Data for PD-1/VEGF ... - BioSpace
WEB6 days ago · HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) presented efficacy data for the first time for its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or without ligufalimab (anti-CD47 antibody AK117) , in combination with FOLFOXIRI as a first-line (1L) treatment for metastatic colorectal cancer ...